Severity on COVID-19 and systemic arterial hypertension: The new hypotheses



Download data is not yet available.


Fang, L, Karakiulakis, G, Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet. Respiratory Medicine. 2020; 8(4): e21.

de Abajo, FJ, Rodríguez-Martín, S, Lerma, V, Mejía-Abril, G, Aguilar, M, García-Luque, A, Elvira, C. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet. 2020.

Tadzic, R, Mihalj, M, Vcev, A, Ennen, J, Tadzic, A, Drenjancevic-Peric, I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney and Blood Pressure Research. 2013; 37(2-3):103-15.

Noris, M, Benigni, A, Remuzzi, G. The case of Complement activation in COVID-19 multiorgan impact. Kidney International. 2020.

Horby, P, Lim, WS, Emberson, JR, Mafham, M, Bell, JL, Linsell, L, Landray, MJ. Dexamethasone in hospitalized patients with Covid-19-preliminary report. The New England journal of medicine. 2020.

Jilma, B, Blann, AD, Stohlawetz, P, Eichler, HG, Kautzky-Willer, A, Wagner, OF. Dexamethasone lowers circulating E-selectin and ICAM-1 in healthy men. Journal of Laboratory and Clinical Medicine. 2000; 135(3): 270-74.




How to Cite

Faria, C. D. de, Schramm Neto, F. A. R., Machado, Y. de J., Correia , D. da S., Batista , L. B. C. A. M., Silva, R. S. A. da, Pitangueira , F. B., Santos , R. A. dos S. e ., Souza, R. A. de, & Silva, R. de B. (2021). Severity on COVID-19 and systemic arterial hypertension: The new hypotheses. Journal of Multiprofessional Health Research, 2(1), e02.24-e02.25. Retrieved from



Letters to the Editor